Tony Abdo, MD
Pulmonary Disease · Oklahoma City, OKNPI 1841555935
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 79 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 18.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,152 and has fallen 87.1% since, to $149 in 2025. That places this record below the midpoint for pulmonary disease clinicians in OK, where the typical reported total is $1,778.
Across 79 payments — averaging $19.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$290
- GSK$234
- Genentech USA, Inc.$152
- Gilead$134
- Boehringer Ingelheim$133
- Merck$69
- plus $532 from 14 others
Across 164 payments — averaging $543.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dompe Farmaceutici S.p.a.$89K
What the payments were for
- Food & beverage$1,544100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 12 | $290 |
| GSK | 15 | $234 |
| Genentech USA, Inc. | 9 | $152 |
| Gilead | 6 | $134 |
| Boehringer Ingelheim | 6 | $133 |
| Merck | 5 | $69 |
| Actelion Pharmaceuticals US, Inc. | 2 | $67 |
| United Therapeutics Corporation | 3 | $64 |
| Sunovion Pharmaceuticals Inc. | 3 | $60 |
| AstraZeneca | 4 | $54 |
| Baxter Healthcare | 2 | $52 |
| Bayer | 3 | $46 |
| Pulmonx Corporation | 1 | $41 |
| La Jolla Pharmaceutical Company | 2 | $39 |
| Portola Pharmaceuticals, LLC | 1 | $34 |
| Edwards Lifesciences | 1 | $18 |
| Insmed, Inc. | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Electromed, Inc. | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $11 |
How this compares
$1,544 in reported general payments places this provider in the 40th percentile of 133 pulmonary disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Spiriva RespimatTiotropium Bromide | 35 | $18,272 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $15,683 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 14 | $5,695 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $5,472 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 67 | $2,565 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 20 | $2,446 |
| Wixela InhubFluticasone Propion/Salmeterol | 14 | $1,033 |
| Azithromycin | 25 | $192 |
| Prednisone | 13 | $43 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $234 | $21,15530 claims |
| Boehringer IngelheimSpiriva Respimat | $133 | $18,27235 claims |
| AstraZenecaBevespi Aerosphere | $54 | $5,69514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 133 pulmonary disease providers in Oklahoma.
Other pulmonary disease in Oklahoma City
- John KingreyOklahoma City$332K
- Fawad ChaudryOklahoma City$80K
- Maroun TawkOklahoma City$62K
- Nathaniel MoultonOklahoma City$28K
- Syed NaqviOklahoma City$15K
- Tarek DernaikaOklahoma City$12K
- Shoab NazirOklahoma City$11K
- Mark GodishOklahoma City$11K
- Mazen ZouwayhedOklahoma City$10K
- Shoaib AhmadOklahoma City$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.